STTK — Shattuck Labs, Inc.
$5.49-1.96%
Last close: · regular session
After-hours $5.49 0.00% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for STTK in the TickerWise workspace.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 44
- Website: https://www.shattucklabs.com
Latest SEC filings for STTK
Latest STTK news
- Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 Read article
- Shattuck Labs (NASDAQ:STTK) Stock Falls 5.3% – Should You Sell? Read article
- Shattuck Labs (NASDAQ:STTK) Shares Climb 11.9% – Here’s Why Read article
- Comparing MDxHealth (NASDAQ:MDXH) & Shattuck Labs (NASDAQ:STTK) Read article
- Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.